The importance of therapeutic recombinant proteins in medicine has led to a variety of tactics to increase their circulation time or to enable routes of administration other than injection. One clinically successful tactic to improve both protein circulation and delivery is to fuse the Fc-domain of immunoglobulin G (IgG) to therapeutic proteins so that the resulting fusion proteins interact with the human neonatal Fc receptor (FcRn). Although successful, Fc-fusion proteins significantly increase molecular weight thereby restricting tissue penetration, decrease protein function, and are limited to mammalian expression systems due to their complex disulfide structure. As an alternative to grafting the high molecular weight Fcdomain to therapeutic proteins, we have modified their N-and/or C-terminus with a short peptide sequence that interacts with FcRn. Methods FcRn binding peptide (FcBP) sequences were genetically fused to the N-and/or C-terminus of model proteins and expressed in E. coli. The interaction between FcBP fusion proteins and FcRn was characterized in vitro through a number of molecular and cell-based assays including surface plasmon resonance, FACS, fluorescence microscopy, and cellular recycling and transcytosis.
